Eli Lilly and Company: updates and filings

LLYNYSEHealthcare · Pharmaceutical Preparations

Price

$1,351.12

November 19, 2026Market cap $1.27T

What Ploutos Investor adds for Eli Lilly and Company

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 71 daysAround Jan 29, 2027 · for Q4 2026

last Oct 29, 2026next Jan 29, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 12, 2026 latest annualOct 29, 2026 latest quarterly
  • Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 29, 2026Results of operations
    Form8-K
  • Oct 19, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 16, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jul 30, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Jul 24, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 24, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 23, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 23, 2026Employee stock plan reportfor the period to Dec 31, 2025
    Form11-K
  • Jun 2, 2026One of its securities removed from an exchange (usually a matured note)
    Form25-NSE
  • May 20, 2026Other material events
    Form8-K
  • May 11, 2026Conflict minerals report
    FormSD
  • May 7, 2026Shareholder vote
    Form8-K
  • May 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Apr 30, 2026Results of operations
    Form8-K
  • Apr 29, 2026Shareholder letter ahead of the meeting
    FormPX14A6G
  • Apr 20, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 31, 2026Filing
    FormDFAN14A
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 20, 2026Additional annual meeting material
    FormDEFA14A
  • Mar 20, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 6, 2026Preliminary proxy statement
    FormPRE 14A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Feb 8, 1994: every report, 8-K, meeting and letter. Of its other filings (1,003 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 65.

The full analysis

What do Eli Lilly and Company's filings show?

The filings are where every one of Eli Lilly and Company's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.